Summary by Moomoo AI
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has announced the nomination of Myrtle Potter and Ross Fubini as independent directors for election at the company's annual meeting on June 13, 2024. The announcement comes as current Board Chair Marijn Dekkers and Nominating and Corporate Governance Committee Chair Reshma Kewalramani are set to retire and not seek reelection. CEO Jason Kelly expressed gratitude for the outgoing members' contributions and enthusiasm for the incoming nominees' expertise. Potter has a significant background in pharmaceutical R&D and corporate leadership, including roles at Sumitomo Pharma America and Genentech. Fubini brings experience from the venture capital sector, having founded XYZ Venture Capital and supported numerous companies. The nominations are part of Ginkgo Bioworks' ongoing efforts to enhance its board's capabilities in cell programming and biosecurity. The company is a leader in providing services across various markets, including food, agriculture, pharmaceuticals, and industrial chemicals. The press release also contains forward-looking statements regarding the potential election of the new directors and the company's future plans.